Chlorfenamine + Phenylephrine + Phenyltoloxamine (Chlorphenaminum + Phenylephrinum + Phenyltoloxaminum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

H1-antihistamines

Included in the formulation
  • Orinol Plus
    capsules inwards 
    Sagmel Inc.     USA
    • АТХ:

    R.01.A.B   Sympathomimetics in combination with other drugs (excluding corticosteroids)

    Pharmacodynamics:

    Chlorphenamine - blocker H1receptors. Has antihistamine, antiserotonin, anticholinergic, sedative effect. Narrows the vessels of the nasal cavity, depresses the symptoms of allergic rhinitis: rhinorrhea, sneezing, itching of the nose and eyes.

    Phenylephrine - α1-adrenomimetic, causes a narrowing of the arterioles and reduces the permeability of the vessels of the nasal mucosa, reduces edema, facilitates breathing, reduces rhinorrhea and lacrimation. Causes dilated pupil without affecting accommodation, lowers intraocular pressure in glaucoma.

    Phenyltoloxamine - sympathomimetic, stimulating α-adrenoreceptors of the mucous membranes of the respiratory tract, has a vasoconstrictive effect, reduces flushing and edema, improves nasal breathing.

    Pharmacokinetics:

    Chlorphenamine

    After ingestion, up to 30% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved after 2.5 hours. The connection with plasma proteins is 70%. The therapeutic effect develops 1 hour after admission and lasts for 24 hours. Penetrates through the blood-brain barrier.

    Metabolism in the liver.

    The elimination half-life is 2 hours. Elimination by the kidneys.

    Phenylephrine

    After ingestion, up to 30% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved after 3 hours. The connection with plasma proteins is 70%. Penetrates through the blood-brain barrier.

    Metabolism in the liver.

    The elimination half-life is 2 hours. Elimination by the kidneys.

    Phenyltoloxamine

    After oral administration, an empty stomach is absorbed up to 40% in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved after 2.5 hours. The connection with plasma proteins is 60%.

    Penetrates through the blood-brain barrier. Metabolism in the liver.

    Half-life is 1.5 hours. Elimination by the kidneys.

    Indications:

    It is used for the treatment of sinusitis and rhinitis, including allergic component.

    ICD-10

    X.J00-J06.J00   Acute nasopharyngitis (runny nose)

    X.J00-J06.J01   Acute Sinusitis

    X.J30-J39.J30   Vasomotor and allergic rhinitis

    Contraindications:

    Pheochromocytoma, arterial hypertension, heart failure, angle-closure glaucoma, bronchial asthma, children under 12 years of age, individual intolerance.

    Carefully:

    Stomach ulcer and duodenal ulcer, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    Inside, 1 capsule every 8-12 hours.

    Side effects:

    Central and peripheral nervous system: drowsiness, headache, agitation, dizziness, tremor, convulsions, hallucinations.

    Hemopoietic system: thrombocytopenia, agranulocytosis.

    Respiratory system: shortness of breath.

    The cardiovascular system: tachycardia, arterial hypertension.

    Digestive system: dry mouth, nausea, anorexia, gastralgia.

    Musculoskeletal system: muscle tremor.

    Dermatological reactions: rash, hyperhidrosis, photosensitivity.

    Sense organs: mydriasis, paresis of accommodation, visual impairment.

    Urinary system: retention of urine.

    Reproductive system: prostate adenoma.

    Allergic reactions.

    Overdose:

    Irritability, headache, arrhythmia, tachycardia, vomiting, hypertension, convulsions.

    Treatment is symptomatic.

    Interaction:

    Incompatible with ethanol.

    It is combined with paracetamol.

    Reduces the hypotensive effect of guanethidine.

    Simultaneous use with monoamine oxidase inhibitors, furazolidone increases the risk of developing hypertension.

    Simultaneous use with halothane increases the risk of ventricular arrhythmia.

    Strengthen sympathomimetic action of tricyclic antidepressants.

    Special instructions:

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up